IHE-RO Technical Committee Face-to-Face Jan 25-28, 2016 at 8:30-5:30, Jan 29 8:30-12:00 ET Melbourne, FL @ Sun Nuclear

Technical Committee Chairs: Scott Hadley, PhD Chris Pauer

IHERO Task Force Co-Chairs Dick Fraass, Ph.D., FAAPM, FASTRO, FACR John Buatti, MD

Mission Statement: The American Society for Radiology Oncology (ASTRO) has formed a multi-society Task Force to undertake an initiative to promote the Integration of the Healthcare Enterprise (IHE) – Radiation Oncology (RO), fostering seamless connectivity and integration of radiotherapy equipment and the patient health information systems. The Task Force will include members from ASTRO, RSNA, American Association of Physicists in Medicine (AAPM), the American College of Radiology (ACR) and the Medical
 Imaging and Technology Alliance (MITA). In addition, members of the International community have also

been invited to participate in IHE-RO. The IHE-RO Task Force, in close collaboration with radiotherapy product manufacturers, will develop appropriate integration profiles for radiation therapy and setup a demonstration of seamless communication among the full array of radiotherapy products.

25

Attendees:

Name	Affiliation	Email	1/25/16	1/26/16	1/27/16	1/28/16	1/29/16
Chris Pauer	Sun Nuclear	chrispauer@sunnuclear.com	Х	X	Х	X	Х
Walter Bosch	Wash. Univ.	bosch@wustl.edu	Х	Х	Х	Х	Х
Uli Busch	Varian	Ulrich.busch@varian.com		X	Х	X	Х
Sven Siekmann	Brainlab	Sven.siekmann@brainlab.com	Х	Х	Х	Х	Х
Jim Percy	Elekta	Jim.percy@elekta.com	Х	Х	Х	Х	Х
Scott Hadley	UMich	swhadley@med.umich.edu	Х	Х	Х	Х	
Koua Yang	Philips	koua.yang@philips.com	Х	Х	Х	Х	Х
Alan Zander	Sun Nuclear	alanzander@sunnuclear.com	Х		Х	X	
Wouter Vreeman	ICT	wouter.vreeman@ict.nl			W		
Harold Beunk	ICT	Harold.beunk@ict.nl			W		
Eli Stevens	Mobius	elis@doselab.com			W		
Mika Mietinnen	Varian				W		
Jennifer Clark	Sun Nuclear	jclark@sunnuclear.com			Х		
Michael Bealer	Sun Nuclear	mbealer@sunnuclear.com			Х		

X = In person W = via Webex

5

10

30

Minutes:

- I. Call to Order (Jan. 25, 2016 at 9:00 am CDT) a quorum was declared.
 - a. Review Agenda
 - b. Other broad topics to add Agenda was revised and approved without objections.
 - c. Minutes from last meetings
 - i. Minutes from IHE-RO TC meeting 9/27/15 in Melbourne, FL were reviewed and approved without objection.
 - ii. Minutes from IHE-RO TC meeting 10/21/15 in San Antonio, TX were reviewed, corrected (location of meeting), and approved without objection.

45 II. Business

- a. Topic 1: Level Set
 - i. Updates on IHE-RO activities
 - 1. Planning
 - 2. Oversight, Steering Committees the TC reviewed minutes from Jan 19 IHE-RO Steering Committee meeting.
 - a. ASTRO has requested an alternate for IHE Board contact: Currently only Bruce Curran.
 - b. **DECISION:** Scott to serve as alternate for IHE Board
 - 3. IHE Domain Coordination Committee (Chris P. and Crystal C.)
 - a. The use of standards in development (e.g., FHIR) in IHE Profiles was mentioned. Such Integration Profiles may also be labeled as "In development".

ii. ASTRO

- 1. Updating the participation agreement in light of IHE Membership fee
 - a. ACTION 160101: Chris P. to check with Crystal on timeframe of participation agreement. Complete as of 1/29/16
- iii. ROSSI (RO Safety Stakeholders Initiative)
 - iv. DICOM WG-7 Update Uli to update when he arrives (updated 1/26/16)
 - 1. 2nd Generation RT Update
 - 2. Update on Change Proposals
 - a. CP1291 adds derivation codes for dose composition
 - b. CP1431 adds effective (vs. physical) beam dose
 - c. CP1559 adds General Reference Module re-uses reference mechanism from General Image Module for other contexts
 - d. CP1530 adds purpose codes in Reference Instance (To be added to TDIC for Cone Beam imaging)
 - e. CP1502 relaxes requirements on Pixel Intensity Relationship (has implications for TPIC, TDIC)
 - 3. Supp 185 Content Assessment IOD review is nearly complete. One open issue related to macros remains. All needed functionality is now in the Supplement.
 - 4. The ROI Supplement is to be reviewed in March WG-06 meeting
- v. MITA
- vi. AdvaMed and Standards Efforts
 - 1. RT2- Radiation Therapy Readiness check (currently in review in preparation for ballot)
 - 2. RT3-Beam Model Standard –scope includes valid geometric and dosimetric parameters for a machine AdvaMed call 1/26/16
 - 3. RT4-(potential) Standard for Machine, Patient QA scope is being defined

 b. Topic 2: Profile Priorities for the Year – The TC feels the highest priorities expressed by the PC are being addressed.

i. **Treatment Delivery Device Integration** is well covered by current and proposed IHE-RO profiles (includes Treatment Record Consistent Content)

35

40

50

55

60

65

70

75

80

85

90	ii. iii.	Radiation Oncology Workflow Exchange (ROWE) is in development in the RO-HIS workgroup – TC reviewed WG minutes from 12/7/15, 1/12/16 User Case Anonymization
		1. ACTION 160102 : Jim P. and Walter B. to evaluate existing profiles (IHE-RAD TF1 Teaching and Clinical Trials Export (TCE) Profile.
	iv.	Brachytherapy – DICOM Subgroup is developing an Integration Profile
95	v.	Authentication / Authorization – It was the consensus of the TC that is not a Rad Onc
		specific issue.
		1. DECISION: Remove this Use Case from further consideration in IHE-RO. Users and
		Enterprise User Authentication (XUA) Profiles
100		Enciprise Oser Autoentication (XOA) Fromes.
100	c. Topic 3	B: Profiles in Public Comment
	i.	TC reviewed comments received for TD*C and TP*C Profiles -
		1. Treatment Delivery – Image Content (TDIC)
		2. Treatment Delivery – Plan Content (TDPC)
105		3. Treatment Planning – Image Content (TPIC)
		4. Treatment Planning – Plan Content (TPPC)
		5. MMRO-III (Multi-Modality Registration) – no comments received
	11.	1 In TPPC (ihe-ro_tppc_v1 10 pc docx): Applicator Geometry Sequence (300A 0431)
110		should be required (R+) for Basic Static Electron beam in TPPC 7.4.4.1.9.2
		2. In TPIC (ihe-ro_tpic_v1.9.doc) Appendix A – change Actor Summary Definition for
		"Treatment Planning Reference Image Content Consumer" to "A system receiving
		reference images to control / correct the position of the patient in a Radiotherapy
115		$\frac{\text{treatment.}}{100}$ (updated 1/26/16)
115		3. In TPIC (ine-ro_tpic_v1.9.doc) Appendix B – change Transaction Definition for KO-
		Radiotherany treatment sessions " (confirmed 1/26/16)
		4. In TPIC (ihe-ro tpic v1.9.doc) in Section 7.3.3.1.1.2 in "Frame of Reference,
		Isocenter and Patient Position"
120		a. The Frame of Reference UID shall be the Frame of Reference UID of the
		referenced RT Plan image instances used to generate the DRR. (updated 1/26/16)
		b. The Patient Position (0018,5100) shall be equal to the Patient Position in
		the RT Patient Setup Module of the referenced RT Plan. (updated
125		1/26/16).
		5. In TPIC (ihe-ro_tpic_v1.9.doc) in Introduction to the Supplement, replace paragraph
		with: This profile defines the content of $2D$ images to be used as reference images
	;;;	(confirmed 1/26/16). Paviaw TDIC comments 1/26/16
130	111.	1 In TDIC (ihe-ro TDIC v1 4 doc) in section 3 Y 1 4 1 2 Message Semantics remove
100		specifications for Study to be used for acquired images.
		2. Add "See Note 1" to Block Sequence (300A,00F4) attribute in section 7.4.7.1.1.2. and
		edit introductory text in this section to clarify reference to Note 1.
	iv.	Next steps – to be discussed later in this meeting.
135	[D]. f l l. 1/25	10.15]
	[Break for lunch 1/25 at [Resume meeting 1/25 at	at 1:15pm]
	d. Topic 4	4.5: ICT work items and plans for 2016
140	i.	A more complete user manual (and examples) for the Custom Content Validator tool would be
		helpful Part of the installation, Click on help button for PDF user manual
	ii.	What rulesets are supported? What limitations are there? Can this approach be used for all
		content profiles? How will the test tools be tested? – One ruleset file is defined per module.
		The for the selects which module the is used.

145	iii. What is Check Dataset vs. Custom Content Validator? Check Dataset is a fileset validator for	Jr
	BRTO (no communication). It does not yet use the new ruleset framework	
	e. Topic 5: Discussion of SAMs Session for IHE-RO at AAPM	
	i. Overall plan 20-30 min each	
	1. Scott – General Overview (20 min)	
150	a. What is IHE? Why aren't standards enough?	
	b. IHE process	
	c. Terminology: Profile, Actor, Transaction, Connectathon	
	d. Content Profile	
	2. Walter – IHE-RO testing (20 min)	
155	a. What is a Connectathon: Live, Structured, Multi-vendor Test Event	
	b. Test tools	
	c. Test data / exchange via Archive	
	d. Fan-in/Fan-out – importance of vendor participation	
	e. Examples: ARTI (TPPC), MMRO-II, TDW-II (?)	
160	3. Chris – Profile Development (20 min)	
	a. Vendor cooperation	
	b. Grand scheme of Planning \rightarrow Delivery for Content and Workflow (Diagram	I)
	c. Safety-related Examples	
	i. QAPV	
165	ii. RXRO	
	iii. CDEB	
	iv. ROIT – Templates – TG-263	
	d. Benefits for patient safety	
	4. Q and A $-$ 30 minutes	
170	ii. ACTION 160103: Scott, Walter, Chris to provide an outline and ~6 questions by mid-May	
	2016	
	f. Topic 6: Survivorship Care Plan	
	i. The TC reviewed the ASTRO Survivorship Care Plan template	
175	(https://www.astro.org/uploadedFiles/Content/Practice Management/SCPTemplate.pdf)	
	1. Much of the information in this form does not typically exist in the Radiation	
	Oncology Information System	
	2. Completion of the form involves input from multiple disciplines.	
	3. Extraction of a summary of a patient's radiation therapy would be helpful. This i	is
180	 Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 	is
180	 Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. It may be helpful to coordinate this effort with ASCO. 	is
180	 Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. It may be helpful to coordinate this effort with ASCO. 	is
180	 Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration 	is
180	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio 	is
180 185	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile 	is
180 185	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple 	is
180 185	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? 	is
180 185	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? 	is
180 185	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. 	is
180 185 190	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. Approach (b) is easier to specify than (a) but may be more difficult to test. 	is
180 185 190	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. Approach (b) is easier to specify than (a) but may be more difficult to test. 	is
180 185 190	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. Approach (b) is easier to specify than (a) but may be more difficult to test. 	is
180 185 190	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. Approach (b) is easier to specify than (a) but may be more difficult to test. 	is
180 185 190	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. Approach (b) is easier to specify than (a) but may be more difficult to test. 	is
180 185 190 195	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. Approach (b) is easier to specify than (a) but may be more difficult to test. [Adjourn for the day 1/25 at 5:20pm] [Resume meeting 1/26 at 8:45am] Updated/confirmed comments received for TD*C and TP*C Profiles with Uli Busch (see section 	is
180 185 190 195	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. Approach (b) is easier to specify than (a) but may be more difficult to test. [Adjourn for the day 1/25 at 5:20pm] [Resume meeting 1/26 at 8:45am] b. Updated/confirmed comments received for TD*C and TP*C Profiles with Uli Busch (see section II.c.ii above)	is
180 185 190 195	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. Approach (b) is easier to specify than (a) but may be more difficult to test. [Adjourn for the day 1/25 at 5:20pm] [Resume meeting 1/26 at 8:45am] h. Updated/confirmed comments received for TD*C and TP*C Profiles with Uli Busch (see section II.c.ii above)	is
180 185 190 195	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. Approach (b) is easier to specify than (a) but may be more difficult to test. [Adjourn for the day 1/25 at 5:20pm] [Resume meeting 1/26 at 8:45am] b. Updated/confirmed comments received for TD*C and TP*C Profiles with Uli Busch (see section II.c.ii above) i. RT3 Discussion with AdvaMed – conference call 11:00am–12:00pm 	is
 180 185 190 195 	 3. Extraction of a summary of a patient's radiation therapy would be helpful. This i likely the most important contribution IHE-RO could make. 4. It may be helpful to coordinate this effort with ASCO. g. Topic 19: Deformable Registration Last discussion was at Oct 2015 TC meeting in San Antonio Begin drafting DRRO Profile What are the Actors? Should we (a) map the MMRO-III Actors or (b) use simple Producer/Consumer pair? How does one demonstrate that a Consumer interprets the DSRO correctly? Approach (b) is similar to ARTI, which only specifies constraints on RT Plan. Approach (b) is easier to specify than (a) but may be more difficult to test. [Adjourn for the day 1/25 at 5:20pm] [Resume meeting 1/26 at 8:45am] h. Updated/confirmed comments received for TD*C and TP*C Profiles with Uli Busch (see section II.c.ii above) i. RT3 Discussion with AdvaMed – conference call 11:00am–12:00pm	is

	i. Discussion of v1.8 of CDEB profile
	1. The profile defines four Actors:
	a. Consistent External Beam Dose Plan Producer & Consumer b. Consistent External Beam Dose Record Producer & Consumer
205	2. Support for single targets is required, support for <i>multiple targets</i> is optional.
200	(Modules for Single and Multiple Targets to be re-ordered for consistency
	DECISION: Treat support for Multiple Targets as an option for CDEB Plan Producers.
	and Consumer Actors. (Separate Actors are not needed.)
210	
	Break for lunch 1/26 at 12:30pm]
	Resume meeting 1/26 at 1:45pm]
	k. Topic 19: Deformable Registration (continued from 1/25/16)
215	i. Uli reviewed the structure of Content and Workflow Profile
	ii. The consensus of the TC is to develop the DRRO using the same type of Actors as MMRO
	and DCOM 1 Deformable Registrator
	2. Deformable Registered Display
220	3. Deformable Registered Contourer
	4. Deformable (General) Registered Dose Display
	5. Deformable Registered Dose Compositor
	6. Deformable Registered Compositing Planner
225	111. New Transactions
223	2 Retrieve DSRO
	3. (Deformed ?) Composite Dose Storage
	iv. Issues specific to Deformable Registration
	1. Finite precision of deformation map
230	2. Finite domain (i.e., extent) of deformation map
	3. Unspecified values (NaN,NaN,NaN)
	4. Pre/Deform/Post non-uniqueness – dest practices?
	6. Direction of transform (Reg \rightarrow Src) is opposite to that for SRO
235	
	1. ROI Templates
	1. An ROI Template supplement proposal is in preparation for presentation to DICOM WG-06 in March 2016 Presentation to WG 06 to include Use Cases (4), proposed approach, main data
	for this IOD diagram showing distribution of templates for a clinical trial
240	ii. Next step is to draft the IHE-RO ROIT profile.
-	1. Two Actors
	a. Template Publisher
	b. Template Consumer
245	c. Validate Segmentation? (optional transaction?)
245	2. IWO Iransactions
	b Read ROI Template Media File
	3. Questions
	a. Media file transport management?
250	b. What is required of a template consumer? At minimum, the user must be able
	to select the template and apply its content while performing segmentation.
	m. IHE-RO PC Call
	i. Members of the TC participated in a monthly call of the IHE-RO Planning Committee.
255	1. ASTRO is not requiring IHE membership for participation in PC or TC meetings.
	2. Jan 31 is deadline for Use Case nominations

260	3. H 4. I 5. U	Email soliciting Use Cases has been sent to all ASTRO members Discussion of Connectathon: volunteer judges, dates/venue, vendor commitment Jse Case prioritization
260	[Adjourn for the day 1/26/16 at 5 [Resume meeting 1/27/16 at 8:30	:30pm] am]
265	n. Topic 12: ICT Sp	print Review and Next Steps (GoToMeeting at 8:30am ET with Wouter Vreeman)
205		Voi 2013 services Migration from Google Code to GitHub, bug tracking
	2	Fool to simplify update of definition files
	3.	Fest tool development
	ii. Overviev	v of released test tools
270	1. I	Definition files 2015b
	2. U	JPS Client Server
	3. (Custom BRTO, MMRO-II, DCOMP (user can use own dataset)
	4. I	BRTO dataset validator
075	5. (Custom Content Validator (rules generated from csv file)
275	6. I	SRTO-II on new test framework (in progress)
	111. Custom (Lontent validator – test content of DICOM file
	1. 0	stens:
	2	a make csv file
280		b. generate module and rules files and fill in rules
		c. make IOD modules overview table .csv file in excel
		d. generate the rules
	iv. New test	framework
• • •	1. I	BRTO-II test tool is being developed in the new framework
285		a. The Content rules generator is used to create a set of basic BRTO content validation
	2. 0	Other profiles will be added into the new framework
		a. Fewer test tools
200		b. Re-use transactions
290		c. Re-use content valuation d Essier to maintain/release
	y Uncomir	a Test tools development
	1. U	Jpdate OAPV
	2. \$	Sup 147 2 nd Gen RT
295	3. U	Jpdate definition files for DICOM 2015D
	4. U	Jpdate dataset validator for MMRO-III
	5. I	mplement CDEB profile
	6. I	mplement QRRO profile
200	7. 1	mplement RXRO profile
300	8. 1	mplement TDIC profile
	9. I 10 I	mplement TDPC profile
	10. I 11 I	Den trial implementation of TSM
	vi IHE-RO	wiki support
305	1.	Fest tool installers and release notes can now be downloaded
	2.	Wiki page has link to GitHub for bug tracking
	vii. Question	s c c c
	1. 4	A more complete user manual (and examples) for the Custom Content Validator tool
_	X	vould be helpful. – This is included in the installation: Click on help button for PDF
310	ι	iser manual.

315	 What rulesets are supported? What limitations are there? Can this approach be used for all content profiles? How will the test tools be tested? – One ruleset file is defined per module. The IOD file selects which module file is used. What is Check Dataset vs. Custom Content Validator? Check Dataset is a fileset validator for BRTO (no communication). It does not yet use the new ruleset from exactly.
	Iramework
	VIII. KFP for hext year s contract has been sent
	2. Support for test tools during Connectation(s)
320	2. Support for test tools during connectation(s)
520	o Topic 13: BRTO-II / Segmentation Profile (Basic RT Objects)
	i Review "Introduction to this Supplement" and Open Issues
	ii Use the term <i>off-slice</i> to refer to contours that do not coincide with CT images slice locations
	and <i>on-slice</i> to refer to contours that coincide with image locations. Include a definition of
325	these terms in the Concepts section of the Profile supplement. Change terminology from
	"high-resolution" contours to "off-slice".
	iii. DECISION: Retain limitation to plans based on <i>CT images</i> .
	iv. Inclusion of the DVH Module in an optional RT Dose storage transaction was proposed.
	Import/display of DVHs may optionally be supported by the Dose Display Actor. (Sven will
330	draft text to be reviewed later.)
	v. Discussion of image resampling: support for multi-series images is not required. However, if
	a Contourer re-samples an image series, it must store the re-sampled image Series instance that
	is referenced by the RT Structure Set it produces.
	vi. Confirmed that dose grid spacing must be regular (i.e., periodic) in X, Y, and Z. However, the
335	row, column, and plane spacing need not be the same.
	vii. Sven will revise profile draft for review $1/28/16$.
	Tania 14 Mid Wash Davan / HIT DO Fatan Diamaian
	p. Topic 14: Mid-week Recap / IHE-RO Future Discussion
340	1. Are we addressing chanenges?
540	2. Frequency of Testing
	2. Challenges of Connectation – How to assure commitment to participate in testing?
	4 IHE-RO Fees for Vendors
	a Find common agreement on what vendors are willing to pay. Need a stable
345	and reliable environment to assure engineering management support for
	participation.
	b. It is difficult for a vendor to justify expense of resources (membership and
	participation) if other vendors are not similarly committed to the process.
	5. Proposals discussed
350	a. ASTRO needs to take leadership as domain sponsor in calling vendors to
	commit to participation.
	b. Set a firm deadline (in May 2016) for Connectathon participation.
	6. IHE-RO Future discussion (to be continued 1/27 afternoon)
~	
355	[Break for lunch 1/27 at 12:30pm]
	[Resume meeting 1/27 at 1:30pm]
	$T_{2} = \frac{1}{2} \left(\frac{1}{2} \left(\frac{1}{2} \right) + \frac{1}{2} \left$
	q. Topic 15: QAPV Updates / Public Comment? (Quality Assurance with Plan Veto)
360	1. Chills reviewed the QAP V Drait Prome and provided an update on DICOM Sup 185 (Content
500	ii Open Issues and Questions
	1 Profile not correct with regard to DICOM supplement – undate terminology to
	"Content Assessment" with Assessment Summary: PASSED / INCONCLUSIVE /
	FAILED FAILED is suggested to link to an outcome of "Major Issues Found"
365	2. QAPV Cross Profile Considerations
	-

370		 a. TDPC – It is anticipated that plans of different beam types will have different requirements and safety checks. b. IHE-RO TF content adherence can be noted in the DICOM Conformance Statement for adhering AEs by reference to supported TDPC Beam Types. 3. Check DICOM Module references to RT Plan IOD Modules for Volume 3, Chapter 7. Look for conflicts in requirements for modules and attributes with TDPC. 4. There is no need to display any plan attributes unless a major issue is found in the guality assessment. This is noted in Massage Samantias.
375		 5. Selection of (QAPV_EQUIVALENT) plans for comparison was discussed. Is a new Actor needed to manage the relationship among RT Plan instances when plans are edited in the TMS?
	r.	IHE-RO Open Session with Sun Nuclear Corporation personnel (2:30-3:30pm)
380	s.	 IHE-RO Future Discussion (continued from 1/27 AM) – Chris has detailed notes i. Are we addressing challenges? 1. Letter to AAPM and ASTRO leaders from TC (see most directly the effects of lagging company support).
385		 Need vendors to re-commit to financial/resource support for IHE-RO Warnings: Connectathon at risk. Process at risk. Unique contributions of IHE-RO – vendor benefits Cost of doing business Sector will start an a dark for previous her TC on Eviden AM
390		 b. Scott will start on a draft for review by IC on Friday AM ii. Need to change TC call data/time What works for everyone? → 3rd Tues of the month at 10:00am ET Connectathon Results and how to publicize – ACTION 160104: Scott to check with Crystal regarding what is needed to publish Connectathon results
395	t.	 Topic 7: Prescription Profile (RXRO) i. Sven reviewed the prescription content (DICOM Sup 147) to be included in this Profile and a summary of the ASTRO Prescription Survey. ii. Prescription usage varies and includes: (a) High-level physician intent, (b) "Wishlist" for treatment planning, (c) Directive for plan optimization, and (d) Post-planning summary (i.e.,
400		 dosimetric objectives achieved by an actual plan). iii. The overall workflow is known (HIS → OIS → TPS → TMS), but details vary by clinic. The initial focus of the Profile is on <i>content</i>. More work is needed to define what workflow considerations should be addressed in this profile.
405		 iv. A range of options for Actors was discussed, including (a) producer and consumer; (b) complete and limited writer, updater, and reader; and (c) more workflow-specific Actors. More work is needed to define v. Example of Options (based on DICOM Modules): Objective Directive
410		 Patient Setup Directive Patient Information Enhanced Object Definition Treatment Directives vi. The consensus of the TC is to concentrate on content for now.
415	ГА J С	 vii. ACTION 160105: Sven to re-cast RXRO as a Content Profile, identifying common clinical "scopes" for prescriptions. Schedule t-con with Scott Hadley and Dr. Neal Martin to evaluate these scope definitions.
	[Aujourn for th	10 uay 1/2//10 at 3.30pm]

[Resume meeting 1/28/16 at 8:40am]

420 u. **NOTE:** Convention for Profile text revisions

i. Use 0.x for drafts prior to Public Comment

	ii. IHE assign 1.0 for initial Public Comment revision
	Tania 17: Treatment Daliusm Becard Content (TDBC)
125	v. Topic 1/: Treatment Derivery Record Content (TDRC)
423	of the RT Beams Treatment Record transferred from TDR Producer to TDR Consumer
	i Discussion of the supplement included
	1 Cross Profile considerations should reference both workflow (TDW-II IPDW
	DPDW) and content (TDPC_CDEB) profiles
430	2. IOD Definitions (RT Treatment Record IOD for Photon External Beam) for both
	Technique-Specific and General Use.
	3. Module requirements for Technique-Specific and General Use
	4. Is time synchronization an important (cross-profile) consideration for TDRC?
	5. Use Case is transfer of RT Treatment Beams Record from Producer (TDD) to
435	Consumer (TMS).
	a. Document a patient's treatment for quality assessment
	b. Document treatment for billing
	c. Machine QA
4.4.0	6. Attribute requirements for RT Beams Session Record Module
440	a. Referenced RT Plan Sequence (Type 2) references the plan that is to be
	treated. Shall be present $(R+)$. A treatment record must reference a plan
	h Referenced Ream Number and Ream Name must be present (R):
	c Beam Description (Type 3): no additional requirements
445	d Primary Fluence Mode (R+*)
	e. Referenced Verification Image Sequence (no additional requirements)
	f. Dose reporting occurs at multiple levels: CP, Beam, and Fraction. There are
	multiple ways to reference doses in the RT Beam Treatment Record.
	i. Referenced Measured Dose Reference Sequence? (Beam level)
450	ii. Referenced Calculated Dose Reference Sequence? (Beam level)
	iii. CDEB Dose Reference (Calculated Dose Reference Module) is at the
	Beam Level.
	g. The Referenced Dose Reference Number links to a dose reference in the RT
155	Plan (CDEB)
455	/. The maximum scope of an RT Beams Treatment Record IOD is a fraction (may be a subset of a fraction)
	subset of a fraction).
	w Topic 10: Ouery / Retrieve Profile (ORRO)
	i. Koua reviewed version 1.6 of the ORRO Profile
460	ii. Actors are Content Retriever and Content Provider
	iii. Query Transactions are by IOD or group of IODs (to specify key attribute requirements). All
	SOP Classes retrieved in IHE-RO profiles should be covered. (Some SOP Classes may be
	grouped.)
	1. RT Structure Set Query
465	2. RT Plan Query
	3. RT Dose Query
	4. RT Image Query
	5. RAD-14 (re-use for Images)
470	6. REG, Deformable REG
470	/ iv. Two Patriaval Transactions are defined:
	1 Instance Retrieval
	2. Series Retrieval
	v. Inter-object references (Instance UIDs) should be supported in the C-Find responses for Ouerv
475	Transactions

480		
	x.	Topic 20.5: BRTO-II DVH
		i. Sven reviewed BRTO-II Profile (revision v0.3)
		ii. Two new Transactions have been introduced to support DVHs
		1. DVH Dose Storage [RO-BRTO-II-3] – Optional transaction in Dosimetric Planner
485		2. DVH Dose Retrieval [RO-BRTO-II-4] – Optional transaction in Dose Viewer
		iii. Retrieval of an existing Dosimetric Plan instance by the BRTO-II Dosimetric Planner was
		discussed. This Transaction is <i>not</i> included in the Profile.
		iv. Handling of QA plans was mentioned. This is an important issue that will be addressed in a
400		separate Profile.
490		v. The DVH content may be stored in the same RT Dose instance as the volumetric dose grid, or it may be stored in a sensate RT Dose instance containing only the DVH information
		It may be stored in a separate KT Dose instance containing only the $D \vee H$ information.
		vii. Two Patient Position Options are defined
		1 Base Setup
495		2. Decubitus Setup
		viii. Review of Attribute requirements for RT DVH Module
		1. Support absolute dose (GY) and volume (CM3)
		2. Cumulative and Differential DVHs
		3. PHYSICAL and EFFECTIVE dose
500		4. Normalization point may not be included
		1x. DECISION: Motion to promote BRTO-II to Public Comment pending corrections from $1/20/16$ line in (-0.4) .
		1/28/16 discussion (v. 0.4). Approved without objection.
		X. ACTION 100100. Sven to incorporate changes in BK10-in drait prome and send to Chris for Public Comment submission to Mary Jungers
505		r uble comment submission to Mary Jungers.
0.00	v.	Topic 20: Brachytherapy and ION IHE-RO efforts
	2	i. The DICOM WG-07 Brachytherapy sub-group has a new chair (Yury Niatsetski). In addition,
		the author of the IHE-RO Profile (Milena Donato) has left the group.
		ii. There are differences in the usage (definition of zero position) of HDR dwell positions among
510		manufacturers. These should be reconciled.
		111. The group is proceeding to incorporate enhancements in 1 st Gen RT using private attributes for
		normalization, source characterization, and dose coordinate transformation.
		Reachytherapy plans is in development
515		Drachytherapy plans is in development.
010	z.	Topic 4: Discuss next steps: RO-HIS (Profile work to bridge RO processes into and out of the Hospital
		Info. System/EHR/EMR)
		i. Uli reported on progress in the RO-HIS group. The group has met 12/715 and 1/12/16.
		ii. Work is in progress on RO-HIS profile using HL7.
520		
	aa.	Topic 18: Patient Safety Workflow Profile
		1. Discussion of information needed to perform plan quality checks before and after treatment delivery. This information includes Treatment Records (often incomplete) and Treatment
		Delivery Logs (non-standard format)
525		ii OA Workflow automation to capture results of quality checks of high-frequency logs EPID
525		images, etc.
		iii. Electronic communication is needed to integrate QA check results in clinical process.
		iv. Next step – assess possible Use Cases.
530	bb.	Topic 19: Deformable Registration
		1. References to DSRO, Plans, Dose should be added to Content Requirements for DRRO. (Also
		ii Data to be retrieved and stored by DRRO Actors was discussed

535	[Adjourn for the day 1/28/16 at 5:35pm] [Resume meeting 1/29/16 at 8:50am]
540	 cc. IHE-RO Future Discussion (continued) i. Draft of letter to AAPM and ASTRO leadership 1. Need to re-establish common commitment of vendors to participation in the IHE-RO test process. ii. Copy to be sent to IHE-RO Task Group chairs and PC chairs.
545	 dd. Future Meetings IHE-RO TC meeting to be held in US May 9-13, 2016 DICOM WG-7 meeting to be held in Munich May 23-27, 2016 ACTION 160107: Walter to check on availability of Wash. U. for May 9-13, 2016 IHE-RO TC Meeting
550	ee. Topic 21: Review Minutes
555	 ff. Topic 22: Review Action Items ACTION 160109: Thomas Schwerer to finalize TDW-II for Public Comment by May TC meeting ACTION 160110: Chris to continue to flesh out QA Workflow ACTION 160111: Chris to update TDRC ACTION 160112: Chris to update CDEB
560	v. ACTION 160113: Chris to prepare QAPV for Public Comment (v. 1.25)
565	 III. Future Meetings a. IHE-RO Meetings i. IHE-RO TC Meeting – May 9-13, 2016 in US (St. Louis, Ann Arbor, or Washington) ii. IHE-RO TC Meeting at ASTRO Annual Meeting – Sep 28 (8:30am-5:30pm) – Oct 1, 2016 (end at 12pm), Boston, MA iii. IHE-RO Connectathon 2016 – Week of Oct 17th (Madison, WI); 1/2-day TC meeting on Saturday to finalize results
570	 b. Other meetings through 2016 ICCR June 27-30, 2016, London AAPM Jul 31-Aug 4, 2016, Washington ASTRO Sep 25-28, 2016 DICOM WG-7 Mar 7-11, 2016, at NEMA, Washington, DC v. DICOM WG-7 May 23-27, 2016, Munich
575	 vi. DICOM WG 7 Aug 25 27, 2010, Multer vi. DICOM WG-7 Aug 4-6, 2016 (after AAPM) in Washington, DC (consider starting Aug 3) vii. DICOM WG-7 Oct 31-Nov 4, 2016 viii. DICOM WG-6 May 30-June 3, 2016, Munich ix. DICOM WG-6 Sep 12-16, 2016, Washington, DC
580	x. DICOM WG-6 Nov 7-11, 2016, Washington, DC

IV. Adjournment – meeting adjourned 1/29/16 at 12:05pm